Stock Events

Stock Events

Racura Oncology 

A$2.83
17
+A$0.08+2.91% Today

Statistics

Day High
2.89
Day Low
2.7
52W High
4.9
52W Low
0.92
Volume
288,824
Avg. Volume
190,783
Mkt Cap
511.72M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebExpected
Q4 2022
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
-0.04
-0.02
-0.01
0
Expected EPS
N/A
Actual EPS
-0.02184784288926363

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-9.57MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RAC.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences is a biopharmaceutical company that develops and markets drugs in areas similar to Race Oncology, including cancer treatments, making it a direct competitor.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb is involved in discovering, developing, and delivering innovative medicines in areas including cancer, competing in the same market as Race Oncology.
AMGEN
AMGN
Mkt Cap189.22B
Amgen focuses on human therapeutics, including oncology/hematology, which pits it against Race Oncology in the cancer treatment sector.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. is a global healthcare company that produces cancer drugs among other pharmaceuticals, directly competing with Race Oncology's offerings.
Pfizer
PFE
Mkt Cap153.13B
Pfizer is a research-based biopharmaceutical company with a broad range of cancer drugs, making it a competitor in the oncology market.
Novartis
NVS
Mkt Cap297.35B
Novartis AG engages in the research, development, manufacturing, and marketing of healthcare products, including oncology, directly competing with Race Oncology.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG specializes in pharmaceuticals and diagnostics with a strong focus on oncology, making it a competitor in the cancer treatment market.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca operates in the biopharmaceutical sector, focusing on the discovery and development of cancer treatments, competing in the same field as Race Oncology.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its pharmaceutical segment, develops and sells oncology drugs, competing with Race Oncology in the healthcare market.
Abbvie
ABBV
Mkt Cap367.8B
AbbVie is a research-driven biopharmaceutical company with a significant focus on oncology, making it a competitor in the cancer treatment market.

About

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin. It has collaborations with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Race Oncology Ltd and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Show more...
CEO
Dr. Peter Michael Smith Ph.D.
Country
Australia
ISIN
AU000000RAC3

Listings

MU
DE
FN3.MU
AU
AU
RAC.AU

0 Comments

Share your thoughts

FAQ

What is Racura Oncology stock price today?▼
The current price of RAC.AU is A$2.83 AUD — it has increased by +2.91% in the past 24 hours. Watch Racura Oncology stock price performance more closely on the chart.
What is Racura Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Racura Oncology stocks are traded under the ticker RAC.AU.
Is Racura Oncology stock price growing?▼
RAC.AU stock has risen by +7.6% compared to the previous week, the month change is a +30.41% rise, over the last year Racura Oncology has showed a +177.45% increase.
What is Racura Oncology market cap?▼
Today Racura Oncology has the market capitalization of 511.72M
When is the next Racura Oncology earnings date?▼
Racura Oncology is going to release the next earnings report on September 01, 2026.
What were Racura Oncology earnings last quarter?▼
RAC.AU earnings for the last quarter are -0.02 AUD per share, whereas the estimation was N/A AUD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Racura Oncology revenue for the last year?▼
Racura Oncology revenue for the last year amounts to 0 AUD.
What is Racura Oncology net income for the last year?▼
RAC.AU net income for the last year is -9.57M AUD.
In which sector is Racura Oncology located?▼
Racura Oncology operates in the Health & Wellness sector.
When did Racura Oncology complete a stock split?▼
The last stock split for Racura Oncology was on November 29, 2023 with a ratio of 21:20.
Where is Racura Oncology headquartered?▼
Racura Oncology is headquartered in Sydney, Australia.